<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124265">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746173</url>
  </required_header>
  <id_info>
    <org_study_id>12-388</org_study_id>
    <nct_id>NCT01746173</nct_id>
  </id_info>
  <brief_title>CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of CHOEP induction chemotherapy followed by autologous stem cell
      transplant using gemcitabine/busulfan/melphalan conditioning in patients with newly
      diagnosed systemic T-cell non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide and
      prednisone)induction chemotherapy followed by autologous stem cell transplant using
      gemcitabine/busulfan/melphalan conditioning in patients with newly diagnosed systemic T-cell
      non-Hodgkin lymphoma.  The study treatment comprises 6 cycles of CHOEP, followed (for
      responding patients) by stem cell mobilization and harvesting (using neupogen +/-
      plerixafor) followed by high dose therapy and autologous stem cell transplantation,
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24 month progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the proportion of patients alive and progression-free after 24 months after the beginning of CHOEP + Gem/Bu/Mel HDT/ASCT among patients younger than 70 years old with untreated TCL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the response rate (completed remission [CR] and partial remission [PR]) after CHOEP x 6 and after Gem/Bu/Mel ASCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival of patients at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 and above toxicity related to study regimen</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To estimate the toxicity (grade 3 and above) with this regimen using CTCAE v4.0.  All grade 3 and above adverse events, and all serious adverse events will be recorded.  This will be reported as number of events and as number of patients with events for all events of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stem cell mobilization rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the rate of successful stem cell mobilization after CHOEP in responding patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who successfully complete regimen</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the proportion of patients who can successfully complete the entire treatment regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment time</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the time to engraftment of neutrophil and platelet engraftment after ASCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the cumulative incidence of relapse at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To estimate the cumulative incidence of treatment-related mortality at 24 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>T-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone Stem Cell Mobilization/Harvest: filgrastim +/- plerixafor Stem Cell Collection by leukapheresis Conditioning Chemotherapy: gemcitabine, busulfan, melphalan, with palifermin support Autologous stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous, on Day 1, 3 or 6 cycles</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Intravenously, on Day 1, 3 or 6 cycles</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Intravenously, on Day 1, 3 or 6 cycles</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Intravenously or orally, Day 1,2 and 3, 3 or 6 cycles</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Taken orally, days 1-5</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Subcutaneous daily injection for 5-7 days</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>neupogen</other_name>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>daily subcutaneous injections for 0-2 days</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Collection</intervention_name>
    <description>Leukapheresis used to collect stem cells from peripheral blood</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Leukapheresis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>Daily intravenous infusion</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>KGF</other_name>
    <other_name>kepivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>intravenous infusion for 2 days</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>gemzaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>intravenous infusion for 4 days</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>intravenous infusion for 2 days</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Reinfusion of stored peripheral blood stem cells</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Stem Cell Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T-Cell lymphoma with mandatory pathologic review at Brigham and Women's
             Hospital or Massachusetts General Hospital

          -  Measurable disease

          -  Candidate for Autologous Stem Cell Transplant

        Exclusion Criteria:

          -  Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation,
             one prior cycle of CHOP or up to 2 prior cycles of CHOEP)

          -  Pregnant or breastfeeding

          -  Alk-positive ACL

          -  Significant neuropathy precluding vincristine administration

          -  Known hypersensitivity to any of the agents used in the treatment

          -  Uncontrolled intercurrent illness

          -  Receiving other investigational agents

          -  History of a different malignancy except if disease free for at least 5 years or have
             cervical cancer in situ or basal cell/squamous cell carcinoma of the skin

          -  HIV positive on anti-retroviral therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Armand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Armand, MD</last_name>
    <phone>6176322305</phone>
    <email>parmand@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Armand, MD</last_name>
      <phone>617-632-2305</phone>
      <email>parmand@partners.org</email>
    </contact>
    <investigator>
      <last_name>Philippe Armand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Armand, MD</last_name>
      <phone>617-632-2305</phone>
      <email>parmand@partners.org</email>
    </contact>
    <investigator>
      <last_name>Philippe Armand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>December 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Philippe Armand, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>T Cell lymphoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
